相关实验视频
Updated: Feb 24, 2026

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
992
神经退行性痴呆症候群的高级神经影像评估:全面多式联络FDG-PET,MR- perfusion和MR-diffusion分析的框架
Joachim Strobel1, Jan Kassubek2, Wolfgang Thaiss3
1Department of Nuclear Medicine, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany; Department of Diagnostic and Interventional Radiology, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
NeuroImage. Clinical
|February 22, 2026
概括
这项研究表明,将[F]氧葡萄糖 (FDG) 射断层扫描 (PET) 与磁共振成像 (MRI) 结合起来,可以区分神经退行性痴呆综合征 (NDS). 这种多式联络方法为NDS亚型提供了更好的诊断准确性.
科学领域:
- 神经成像是一种神经成像.
- 放射化学 放射化学是指辐射化学.
- 神经学 神经学
背景情况:
- 化氧葡萄糖 (FDG) 定子发射断层扫描 (PET) 是用于成像神经退行性痴呆综合征 (NDS) 的标准.
- 先进的多式磁共振成像 (MRI) 可以补充PET成像用于NDS的差异诊断.
研究的目的:
- 评估一种新的方法,整合来自同时FDG-PET/MRI的代谢, perfusion 和微结构数据.
- 使用这种综合方法,识别不同NDS亚型的不同成像签名.
主要方法:
- 66名NDS患者 (包括阿尔茨海默病,前性痴呆症和初级渐进性失语变体) 和10名主观认知缺陷 (SCD) 患者接受了FDG-PET/MRI组合.
- 使用伪连续动脉旋转标记 (pCASL) 进行 perfusion 和扩散张力成像 (DTI) 进行微观结构分析.
- 在基于兴趣区域 (ROI) 的标准化吸收值 (SUV),大脑血流 (CBF) 和分数异构 (FA) 上使用支持矢量机器 (SVM),以区分NDS子组和SCD.
主要成果:
- 确定了与SUV和CBF变化相邻的区域的白质变化.
- 使用SVM根据ROI参数区分NDS子组和SCD,实现了高分类准确率 (81%94%).
结论:
- 结合FDG-PET和MRI提供了一种多式神经成像方法,有可能提高NDS的诊断能力.
- 这一框架显示了早期NDS诊断的前景,对于有效的患者管理至关重要,并保证了临床整合的进一步发展.
相关概念视频
Assessment of Diffusion and Perfusion
1.8K
Understanding and evaluating diffusion and perfusion is critical in assessing a patient's respiratory and circulatory health. These processes play key roles in maintaining the body's internal environment, ensuring that tissues receive adequate oxygen while waste products are efficiently removed.
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
The Role of Diffusion in Respiration
Diffusion is the process by which molecules move from an area of higher concentration to an area of lower concentration. In the respiratory system, this...
1.8K
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K

![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)